Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03978442 · ClinicalTrials.gov registry record · Phase 4
CPT-SMART for Treatment of PTSD and Cigarette Smoking
A Phase 4 study of Smoking and Stress Disorders, Post-Traumatic, sponsored by VA Office of Research and Development.
- Completed
- Registry status
- Phase 4
- Development phase
- 120
- Enrollment target
- 1
- Study location
NCT03978442: Completed Phase 4 study of Smoking and Stress Disorders, Post-Traumatic, sponsored by VA Office of Research and Development.
NCT03978442 is a Phase 4 study of Smoking and Stress Disorders, Post-Traumatic that has completed, run by VA Office of Research and Development. The registered enrollment target is 120 participants, below the 454-participant average among 123 other Smoking trials with a reported enrollment target (74% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03978442, a Phase 4 study of Smoking and Stress Disorders, Post-Traumatic, has completed, sponsored by VA Office of Research and Development.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 120 participants
- Enrollment target
- 1
- Study location
Study Summary
Smoking is the leading cause of preventable illness, disability, and death in the United States. The rate of smoking is disproportionately higher among Veterans with posttraumatic stress disorder (PTSD). Unfortunately, smoking cessation efforts that are effective in the general population have shown limited effectiveness in smokers with PTSD. The high smoking rate and difficulty with achieving abstinence indicate a critical need to develop effective interventions for Veterans who smoke and have PTSD. The investigators' data indicate that negative emotions and trauma reminders are associated with relapse for smokers with PTSD. In this context, an ideal strategy may be to combine evidence-based PTSD treatment with intensive smoking cessation treatment to maximize quit rates. Cognitive processing therapy (CPT) is a well-established evidence-based treatment for PTSD. The investigators have successfully developed a treatment manual that combines CPT with cognitive-behavioral counseling for smoking cessation. Contingency management (CM) is another intensive behavioral treatment that has been shown to help with reducing smoking. CM provides positive reinforcers such as money to individuals misusing substances contingent upon abstinence from use. The primary goal of this study is to evaluate the efficacy of a treatment that combines CM with cognitive-behavioral smoking cessation counseling, smoking cessation medication, and CPT. Proposed is a randomized, two-arm clinical trial in which 120 Veteran smokers with PTSD will be randomized to either: 1) COGNITIVE PROCESSING THERAPY with SMOKING ABSTINENCE REINFORCEMENT THERAPY (CPT-SMART) or 2) COMBINED CONTACT CONTROL, an intervention identical to CPT-SMART in PTSD and smoking treatment, except for using payment that is not contingent on abstinence. Specific aims include: AIM 1) To evaluate the efficacy of CPT-SMART on rates of short- and long-term abstinence from cigarettes; AIM 2) To evaluate the impact of CPT-SMART on treat
Primary Outcome
7-day point prevalence abstinence is defined as no smoking in the prior 7 days.
Conditions Studied
Interventions
- BEHAVIORAL Cognitive Processing Therapy
- DRUG Bupropion
- BEHAVIORAL Smoking Cessation Cognitive Behavioral Therapy (CBT)
- BEHAVIORAL Smoking Abstinence Reinforcement Therapy
- BEHAVIORAL Yoked Contingency Management
Study Locations (1)
North Carolina
- Durham VA Medical Center, Durham, NC - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2019-11-07 |
| Est. Completion | 2025-10-08 |
| Phase | Phase 4 |
What the finished NCT03978442 record still lists
NCT03978442 is an interventional study that assigns participants to a tested intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap, below the 454-participant average among 123 other Smoking trials with a reported enrollment target (74% lower).
The record links to 2 conditions, with Smoking appearing as the primary indexed condition, and to 5 interventions - of which Cognitive Processing Therapy is the first listed.
NCT03978442 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT03978442 about?
NCT03978442 is a clinical study titled "CPT-SMART for Treatment of PTSD and Cigarette Smoking". Smoking is the leading cause of preventable illness, disability, and death in the United States. The rate of smoking is disproportionately higher among Veterans with posttraumatic stress disorder (PTSD). Unfortunately, smoking cessation efforts that are effective in the general population have shown...
What is the current status of trial NCT03978442?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 120 participants. The study started on 2019-11-07. Estimated completion is 2025-10-08.
What conditions does trial NCT03978442 study?
This clinical trial studies the following conditions: Smoking, Stress Disorders, Post-Traumatic.
What interventions are being tested in trial NCT03978442?
The interventions under investigation include: Cognitive Processing Therapy (BEHAVIORAL), Bupropion (DRUG), Smoking Cessation Cognitive Behavioral Therapy (CBT) (BEHAVIORAL), Smoking Abstinence Reinforcement Therapy (BEHAVIORAL), Yoked Contingency Management (BEHAVIORAL).
Who is sponsoring clinical trial NCT03978442?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03978442 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Smoking
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03978442's enrollment target sits among peer trials
120 65th of 123 higher than 59 of 123 other Smoking trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Smoking trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Modifying Progesterone and Estradiol Levels to Prevent Postpartum Cigarette Smoking Relapse and Reduce Secondhand Smoke Exposure in Infants and Children
RECRUITING · Phase 4
-
Identifying Treatments to Motivate Smokers to Quit
COMPLETED · Phase 4
-
Smoking Tobacco and Drinking Study
COMPLETED · Phase 4
-
Bupropion for Hospitalized Smokers With Acute Cardiovascular Disease
COMPLETED · Phase 4
-
Long-term Varenicline Treatment for Smoking Cessation
COMPLETED · Phase 4
-
Bupropion SR Plus Counseling for Smoking Cessation
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01174108 · 120 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
- NCT01627301 · 120 participants · NA
Sympathetic Overactivity in Post-traumatic Stress Disorder
- NCT02025023 · 120 participants · Phase 3
Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study
- NCT02128906 · 120 participants · Phase 2
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI